Latest ACUTA CAPITAL PARTNERS, LLC Stock Portfolio
$153Million– No. of Holdings #33
ACUTA CAPITAL PARTNERS, LLC Performance:
2024 Q1: 27.7%YTD: 27.7%2023: 13.8%
Performance for 2024 Q1 is 27.7%, and YTD is 27.7%, and 2023 is 13.8%.
About ACUTA CAPITAL PARTNERS, LLC and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, ACUTA CAPITAL PARTNERS, LLC reported an equity portfolio of $153.9 Millions as of 31 Mar, 2024.
The top stock holdings of ACUTA CAPITAL PARTNERS, LLC are OCUL, PRAX, MRSN. The fund has invested 15.6% of it's portfolio in OCULAR THERAPEUTIX INC and 6.4% of portfolio in PRAXIS PRECISION MEDICINES I.
The fund managers got completely rid off RAYZEBIO INC, CYMABAY THERAPEUTICS INC (CBAY) and EYEPOINT PHARMACEUTICALS INC (EYPT) stocks. They significantly reduced their stock positions in KURA ONCOLOGY INC. (KURA), CELLECTAR BIOSCIENCES INC. (CLRB) and ARCELLX INC (ACLX). ACUTA CAPITAL PARTNERS, LLC opened new stock positions in AGIOS PHARMA (AGIO), ORIC PHARMACEUTICALS INC (ORIC) and MEREO BIOPHARMA GROUP PLC (MREO). The fund showed a lot of confidence in some stocks as they added substantially to ENLIVEN THERAPEUTICS INC, INSMED INC (INSM) and OCULAR THERAPEUTIX INC (OCUL).
The top stock holdings of ACUTA CAPITAL PARTNERS, LLC are OCUL, PRAX, MRSN. The fund has invested 15.6% of it's portfolio in OCULAR THERAPEUTIX INC and 6.4% of portfolio in PRAXIS PRECISION MEDICINES I.
The fund managers got completely rid off RAYZEBIO INC, CYMABAY THERAPEUTICS INC (CBAY) and EYEPOINT PHARMACEUTICALS INC (EYPT) stocks. They significantly reduced their stock positions in KURA ONCOLOGY INC. (KURA), CELLECTAR BIOSCIENCES INC. (CLRB) and ARCELLX INC (ACLX). ACUTA CAPITAL PARTNERS, LLC opened new stock positions in AGIOS PHARMA (AGIO), ORIC PHARMACEUTICALS INC (ORIC) and MEREO BIOPHARMA GROUP PLC (MREO). The fund showed a lot of confidence in some stocks as they added substantially to ENLIVEN THERAPEUTICS INC, INSMED INC (INSM) and OCULAR THERAPEUTIX INC (OCUL).
ACUTA CAPITAL PARTNERS, LLC Equity Portfolio Value
Last Reported on: 15 May, 2024
ACUTA CAPITAL PARTNERS, LLC Annual Return Estimates Vs S&P 500
Our best estimate is that ACUTA CAPITAL PARTNERS, LLC made a return of 27.7% in the last quarter. In trailing 12 months, it's portfolio return was 48.75%.
New Buys
| Ticker | $ Bought |
|---|---|
| agios pharma | 1,615,860 |
| oric pharmaceuticals inc | 1,429,890 |
| mereo biopharma group plc | 1,313,020 |
| lyra therapeutics inc | 1,078,050 |
| ultragenyx pharmaceutical inc | 933,800 |
| intra-cellular therapies inc. | 920,360 |
New stocks bought by ACUTA CAPITAL PARTNERS, LLC
Additions
| Ticker | % Inc. |
|---|---|
| enliven therapeutics inc | 219 |
| insmed inc | 109 |
| ocular therapeutix inc | 101 |
| celldex therapeutics inc | 57.06 |
| applied therapeutics inc | 50.83 |
| dyne therapeutics inc | 24.8 |
| tourmaline bio inc | 12.6 |
Additions to existing portfolio by ACUTA CAPITAL PARTNERS, LLC
Reductions
| Ticker | % Reduced |
|---|---|
| kura oncology inc. | -87.17 |
| cellectar biosciences inc. | -69.95 |
| arcellx inc | -55.19 |
| praxis precision medicines i | -45.83 |
| disc medicine inc | -33.51 |
| viridian therapeutics inc | -29.15 |
| hillevax inc | -22.79 |
| immunovant inc | -22.72 |
ACUTA CAPITAL PARTNERS, LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| cymabay therapeutics inc | -11,624,700 |
| eyepoint pharmaceuticals inc | -9,824,710 |
| rayzebio inc | -23,504,600 |
| an2 therapeutics inc | -2,704,680 |
| apellis pharmaceuticals inc | -4,555,350 |
| 4d molecular therapeutics inc | -1,509,370 |
| centessa pharmaceuticals plc | -303,578 |
| verona pharma plc | -377,720 |
ACUTA CAPITAL PARTNERS, LLC got rid off the above stocks
Sector Distribution
ACUTA CAPITAL PARTNERS, LLC has about 87.6% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 87.6 |
| Others | 12.4 |
Market Cap. Distribution
ACUTA CAPITAL PARTNERS, LLC has about 5.4% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| SMALL-CAP | 46.6 |
| MID-CAP | 23.3 |
| UNALLOCATED | 12.4 |
| MICRO-CAP | 8.9 |
| LARGE-CAP | 5.4 |
| NANO-CAP | 3.5 |
Stocks belong to which Index?
About 62.2% of the stocks held by ACUTA CAPITAL PARTNERS, LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 62.2 |
| Others | 37.8 |
ACUTA CAPITAL PARTNERS, LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of ACUTA CAPITAL PARTNERS, LLC
ACUTA CAPITAL PARTNERS, LLC has 33 stocks in it's portfolio. About 62.2% of the portfolio is in top 10 stocks. VRDN proved to be the most loss making stock for the portfolio. PRAX was the most profitable stock for ACUTA CAPITAL PARTNERS, LLC last quarter.
Last Reported on: 15 May, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| AADI | aadi biosciences inc | 2.81 | 1,849,400 | 4,327,600 | unchanged | 0.00 | ||
| ACLX | arcellx inc | 1.56 | 34,500 | 2,399,480 | reduced | -55.19 | ||
| AGIO | agios pharma | 1.05 | 55,262 | 1,615,860 | new | |||
| ANTX | an2 therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| APLS | apellis pharmaceuticals inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| APLT | applied therapeutics inc | 3.50 | 792,000 | 5,385,600 | added | 50.83 | ||
| ARGX | argenx se - adr | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CBAY | cymabay therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CLDX | celldex therapeutics inc | 2.97 | 109,000 | 4,574,730 | added | 57.06 | ||
| CLRB | cellectar biosciences inc. | 0.37 | 143,500 | 571,130 | reduced | -69.95 | ||
| CNTA | centessa pharmaceuticals plc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CRNX | crinetics pharmaceuticals | 2.38 | 78,403 | 3,670,040 | reduced | -10.4 | ||
| DYN | dyne therapeutics inc | 3.40 | 184,500 | 5,237,960 | added | 24.8 | ||
| EYPT | eyepoint pharmaceuticals inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| FDMT | 4d molecular therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| HLVX | hillevax inc | 2.71 | 250,609 | 4,167,630 | reduced | -22.79 | ||
| IMVT | immunovant inc | 1.94 | 92,346 | 2,983,700 | reduced | -22.72 | ||
| INSM | insmed inc | 1.09 | 61,718 | 1,674,410 | added | 109 | ||
| ITCI | intra-cellular therapies inc. | 0.60 | 13,300 | 920,360 | new | |||
| KURA | kura oncology inc. | 1.25 | 90,000 | 1,919,700 | reduced | -87.17 | ||